草酸艾司西酞普兰联合利培酮治疗精神分裂症后抑郁患者的疗效和安全性  

Efficacy and safety of Escitalopram oxalate combined with Risperidone in treatment of depression after schizophrenia

作　　者：杨猛[1] 杨红梅[1] 毕艳芳[2] 孟超[1] 梁家騋[1] 

机构地区：[1]济南市精神卫生中心,山东济南250032 [2]山东省胸科医院

出　　处：《中国民康医学》2017年第4期13-14,28,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察草酸艾司西酞普兰联合利培酮治疗精神分裂症后抑郁患者的疗效和安全性。方法:将符合精神分裂症后抑郁标准的60例患者随机分为研究组和对照组,每组各30例。研究组患者给予草酸艾司西酞普兰联合利培酮治疗;对照组给予利培酮治疗。两组患者的疗程均为8周。治疗后,采用汉密尔顿抑郁量表(HAMD)和阴性与阳性症状量表(PANSS)评定两组患者的疗效和安全性。结果:研究组患者的HAMD治疗2周、4周、8周末与治疗前评分比较差异有统计学意义(P<0.05或P<0.01);治疗8周末与治疗前,对照组患者的评分比较差异有统计学意义(P<0.05);治疗2周、4周、8周末,两组患者比较差异有统计学意义(P<0.05或P<0.01)。治疗2周、4周、8周末,研究组患者的PANSS比较差异有统计学意义(P<0.05或P<0.01);治疗4周末及8周末,对照组患者的阴性症状、精神病理及总分减分与治疗前减分比较差异有统计学意义(P<0.05或P<0.01)。研究组患者显效率63.33%,对照组患者显效率26.67%,两组患者的显效率比较差异有显著统计学意义(P<0.01)。两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论:草酸艾司西酞普兰合联合培酮治疗精神病后抑郁症患者的疗效优于单纯利培酮治疗疗效,安全性相当。Objective： To investigate efficacy and safety of Escitalopram oxalate combined with Risperidone in treatment of de-pression after schizophrenia. Methods ： 60 patients meeting the criteria of depression after schizophrenia were randomly divided into study group （n = 30, Escitalopram oxalate combined with Risperidone） and control group （n = 30, single Risperidone. The treatment lasted for 8 weeks. After the treatment, the efficacy and safety were assessed by Hamilton depression scale （ HAMD） and positive and negative symptom scale （PANSS）. Results ： The differences of the HAMD scores of the study group among before and 2,4, and 8 weeks after the treatment were statistically significant （ P〈0. 05 or P〈0. 01） , and that of the control group before and 8 weeks after the treatment was also statistically significant （ P〈0.05）. There were significant differences in the HAMD score between the two groups 2, 4, and 8 weeks after the treatment （P〈0. 05 or P〈0. 01）. Further, the differences of the PANSS scores of the study group 2,4, and 8 weeks after the treatment were statistically significant （ P〈0. 05 or P〈0. 01）. In the control group, there were significant differences in the negative symptom score, mental pathology score, and reduction in the total score among before and 2,4, and 8 weeks after the treatment were statistically significant （ P 〈0 . 05 or P 〈0 . 01 ） . The obvious effective rates of study group and control group were 63. 33% and 26. 67% , respectively, and the difference was significant（P〈0. 01）. The difference of the incidence of adverse reactions between the two groups was not statistically significant （P〉0. 05）. Conclusions ： Escitalopram oxalate combined with Risperidone in the treatment of depression after schizophrenia has better efficacy than and equivalent safety to single Risperidone.

关 键 词：精神分裂症 抑郁症 草酸艾司西酞普兰 利培酮 

分 类 号：R749.3[医药卫生—神经病学与精神病学]